Thermo Fisher Scientific Inc. $TMO Shares Sold by Mascoma Wealth Management LLC

Mascoma Wealth Management LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,134 shares of the medical research company’s stock after selling 102 shares during the period. Mascoma Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $460,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at about $30,000. Keystone Global Partners LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. grew its holdings in Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after acquiring an additional 61 shares during the period. Finally, HighMark Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on TMO shares. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $543.88 on Friday. The company has a market cap of $205.37 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The stock’s 50 day simple moving average is $482.58 and its 200-day simple moving average is $447.27. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.